Has Thomas Orgeron, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,437 in general payments to Thomas Orgeron, MD across 381 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thomas Orgeron, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thomas Orgeron, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thomas Orgeron, MD

General Practice · Slidell, LANPI 1922322940

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,437in general payments, 2019–2025

Across 381 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$782
Novartis$718
Sanofi$713
Pfizer$584
Regeneron Healthcare Solutions, Inc.$544
AbbVie$541
plus $2K from 15 others

What the payments were for

Food & beverage$5,33998%
Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	49	$782
Novartis	66	$718
Sanofi	43	$713
Pfizer	38	$584
Regeneron Healthcare Solutions, Inc.	36	$544
AbbVie	52	$541
E.r. Squibb & Sons, L.L.C.	27	$396
LEO Pharma Inc.	19	$325
UCB, Inc.	12	$231
Galderma Laboratories, L.p.	18	$175
Sun Pharmaceutical Industries Inc.	7	$120
Johnson & Johnson	5	$86
Sanofi-aventis U.S. LLC	1	$80
Mimedx Group, Inc.	1	$22
Genentech USA, Inc.	1	$21
Biofrontera Inc.	1	$18
Organogenesis Inc.	1	$17
AstraZeneca	1	$17
Incyte Corporation	1	$17
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$16
Lilly USA, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EUCRISA$125

How this compares

$5,437 in reported general payments places this provider in the 95th percentile of 1,221 general practice providers in Louisiana.

See all general practice providers in Louisiana →

Medicare billing

Part B allowed, 2024

$434,574

Medicare patients

336

Services billed

5,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent SyringeDupilumab	114	$432,683
OtezlaApremilast	73	$347,221
Dupixent PenDupilumab	72	$283,372
Cosentyx Sensoready (2 Pens)Secukinumab	23	$236,305
OdomzoSonidegib Phosphate	14	$189,896
Humira(Cf) PenAdalimumab	11	$74,681
Clobetasol Propionate	173	$5,569
Doxycycline Monohydrate	250	$3,887
Betamethasone Valerate	89	$2,800
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	87	$2,240
Doxycycline Hyclate	26	$2,156
Triamcinolone Acetonide	91	$1,603
ValacyclovirValacyclovir Hcl	32	$1,367
Ibuprofen	233	$947
Metronidazole	11	$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenOtezla	$782	$347,22173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 general practice providers in Louisiana.